#Superluminal ltd israel pdf
#Superluminal ltd israel license
#Superluminal ltd israel free

Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar. QUANTUM GENOMICS: Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar. Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar Quantum Genomics inks licensing nd production deal for firibastat Quantum Genomics signs license and production agreement with Julphar

#Superluminal ltd israel free

Receive by email the next press releases of the company by registering on it's free

#Superluminal ltd israel pdf

Full and original release in PDF format:

SECURITY MASTER Key: yJiekcWYk5yVyXBulJaabWdraGtkw2SaZ2jInJZvl5jJbm6TyZiVa5XJZnBjlmZn +1 (646) 751-4362 - This publication embed 'Actusnews SECURITY MASTER'. More information on our Twitter and LinkedIn accounts Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant hypertension (in approximately 30% of patients it is poorly controlled or treatment failure occurs), and heart failure (one in two patients diagnosed dies within five years).Д«ased in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and the US market OTCQX (symbol: QNNTF). Catherine Llorens-CortГЁs at the CollГЁge de France. It is the only company in the world to pursue this innovative approach directly targeting the brain, founded upon more than twenty years of research work by Paris-Descartes University and the INSERM/CNRS laboratory led by Dr. Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the Brain Aminopeptidase A Inhibition (BAPAI) mechanism.

Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. 'Teva Israel has a robust and wide medicine portfolio, which consists of hundreds of generic, specialty and OTC medicines supporting most of Israel's medical needs, firibastat is an important addition to our value proposition in the field of cardiovascular diseases.' and Cluster Head of Israel, Ukraine, South Africa & MEA. 'We are very pleased to collaborate with Quantum Genomics in order to tackle together a substantial unmet need and introduce firibastat an innovative treatment to our Israeli patients suffering from resistant and difficult-to-treat hypertension', said Yossi Ofek, CEO of Teva Israel Ltd. We're already talking about extending this exclusive license to new territories where Teva operates,' said Jean-Philippe Milon, CEO of Quantum Genomics.

We're proud to be partnering one of the pharmaceutical industry's biggest successes, which is sure to make firibastat a leading technology in its category. Its expertise and reputation are beyond doubt, as shown by its incredible management of the Covid-19 vaccination campaign in Israel. 'Teva is now one of the world's largest pharmaceutical companies. Quantum Genomics will receive payments of up to $11 M and 25% minimum up to 30% royalties on future firibastat sales.